Daily Care News for November 6, 2019
advertisement
- Insulin Glargine 300 Units/mL Effective in Pediatric T1D Patients
- RT-CGM in adults with type 1 diabetes improves both glycaemic and patient-reported outcomes, but independent of each other (HTML)
- The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies (HTML See also: Flash glucose monitoring: Impact on markers of glycaemic control and patient-reported outcomes in individuals with type 1 diabetes mellitus in the real-world setting)
- Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries (HTML)
- Mini-doses of glucagon to prevent hypoglycemia in children with type 1 diabetes refusing food: a case series (HTML)
- Diabetes stigma, parent depressive symptoms and Type-1 diabetes glycemic control in India
- Assessing Health-Related Quality of Life in Children and Adolescents with Diabetes: Development and Psychometrics of the Type 1 Diabetes and Life (T1DAL) Measures (HTML)
- Iterative development of a web-based intervention for families of young children with type 1 diabetes: DIPPer Academy
- A mHealth Support Program for Australian Young Adults with Type 1 Diabetes: A Mixed Methods Study (HTML)
- Predictors of Large-for-Gestational-Age Birthweight Among Pregnant Women With Type 1 and Type 2 Diabetes: A Retrospective Cohort Study (HTML)
- Frequency of injection site assessment for lipohypertrophy in children and young people with type 1 diabetes
- Community health workers and the care of children with type 1 diabetes (HTML)
- Hypoglycaemia unawareness in young people with type 1 diabetes transferred to an adult center (HTML, also in Spanish)
- Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study (HTML)
- Rapid increase in the incidence of end-stage renal disease in patients with type 1 diabetes having HbA1c 10% or higher for 15 years (HTML)
- Dapagliflozin: A Review in Type 1 Diabetes (HTML)
